Mabworks Plans Hong Kong IPO to Support Antibody/Multi-Specifics Pipeline
July 21, 2021 at 07:07 AM EDT
Beijing Mabworks Biotech has filed an application to IPO on the Hong Kong Exchange. The company is developing mAbs and multi-specific antibodies for oncology and autoimmune diseases. Its pipeline consists of six clinical-stage drug candidates and six preclinical candidates, plus an Avastin biosimilar that Mabworks out-licensed to Betta Pharma of Hangzhou. The company's lead candidate is MIL62, a third-gen CD20 multi-specific that is slated to begin Phase III trials in lymphoma. Because the application was the first filing, no financial details of the IPO were included. More details.... Share this with colleagues: // //
